Tag: CLTI
BEST-CLI: Trial results endure in analysis of patients who presented with...
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of...
Incorporation of Shockwave E8 Peripheral IVL into the treatment of patients...
This advertorial is sponsored by Shockwave Medical.
Anand Prasad, MD, an 18-year veteran of vascular and endovascular medicine with a particular interest in peripheral arterial...
Research suggests arm vein is the best alternative bypass conduit to...
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI)...
The top 10 most popular Vascular Specialist stories of October 2024
In October, the most read stories from Vascular Specialist included a new leadership announcement from the American College of Surgeons (ACS); study results examining a...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of...
R3 Vascular today announced that the Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
Endoscopic vein harvest under the microscope
Conflicting results open fresh debate around effect of vein harvesting technique on long-term patency of lower extremity bypass grafts.
Two separate analyses that looked at...
The Shockwave E8 experience: Featuring the new Shockwave peripheral IVL workhorse
This advertorial is sponsored by Shockwave Medical.
Paul J. Foley III, MD, a vascular surgeon and director of the non-invasive vascular lab at Doylestown Hospital...
Smoking: BEST-CLI trial points to protective effect against MALE in those...
An analysis of the BEST-CLI randomized controlled trial (RCT) found that smokers with chronic limb-threatening ischemia (CLTI) should be preferentially treated with open bypass...
The top 10 most popular Vascular Specialist stories of September 2024
In September, the most read stories from Vascular Specialist included a change in leadership for the Midwestern Vascular Surgical Society; study results examining new treatment...
The CLTI conundrum: My spirited journey through the CLTI saga
Welcome to the CLTI Chronicles, a saga of mystery, medicine and misadventures in limb salvage unfolding weekly in my office, where the drama of...
VQI analysis of CLTI practice following BEST-CLI finds no pick up...
A Vascular Quality Initiative (VQI) analysis of evolving practice in the wake of the BEST-CLI trial demonstrated no increase in the rate of surgical...
Pilot study looks at undiagnosed vascular disease in homeless
A pilot study in Canadian capital Ottawa aimed at uncovering the extent of undiagnosed vascular disease among the city’s homeless population detected a subset...
‘Select CLTI patients may be safely treated in the office-based lab’
Results from a single-center analysis show the outpatient setting met SVS objective performance goals.
A retrospective study of endovascular interventions performed for chronic limb-threatening ischemia...
Vascular Specialist–September 2024
In this issue:
‘Select CLTI patients may be safely treated in the office-based lab’: Single-center analysis finds outpatient setting met SVS objective performance goals
...
Shockwave Medical expands US peripheral IVL portfolio with enhanced catheter
Shockwave Medical, part of Johnson & Johnson MedTech, has announced the full U.S. launch of its Shockwave E8 peripheral intravascular lithotripsy (IVL) catheter, following...
The top 10 most popular Vascular Specialist stories of August 2024
In August, the most read stories from Vascular Specialist included a research letter addressing ‘alarmingly high’ mortality rates in chronic limb-threatening ischemia (CLTI) patients; a new...
SCOREPAD seeks to address ‘alarmingly high’ mortality in CLTI patients with...
A new research letter underscores the need to improve long-term survival following lower extremity revascularization for chronic limb-threatening ischemia (CLTI), setting out a randomized...
CIRSE begins CALCIO trial enrolment for treatment of CLTI with Shockwave...
The Cardiovascular and Interventional Society of Europe (CIRSE) have announced that patient enrolment for the CALCIO trial has begun. CALCIO started patient enrolment on...
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention,...
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless...
Vascular Specialist@VAM Conference Edition 3
In this issue:
Chickasaw Nation study exemplifies how diversity can boost patient access to specialized vascular care
Young vascular surgeons on the PAD frontier:...
Sex-based analysis finds BEST-CLI data generalizable to female patients
A new secondary analysis of sex disparities in the best endovascular versus best surgical therapy in patients with critical limb ischemia (BEST-CLI) trial data...
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention,...
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless...
VAM 2024: Enhancing clinical practice and patient interaction in CLTI
A key event on informed decision-making in chronic limb-threatening ischemia (CLTI) promises to be a highlight of the 2024 Vascular Annual Meeting (June 19–22). Funded...
The role of deep venous arterialization comes under scrutiny
"Every so often in vascular disease, disruptive technologies come along and the question really is, ‘Is this going to make a big impact on...
PAD guideline update from ACC, AHA and others centers multispecialty care
New multisociety clinical practice guidelines for the management of lower extremity peripheral arterial disease (PAD) have been published online in the Journal of the...
‘Who let a vascular surgeon in the room?’: Leadership in the...
Leading vascular surgeons from across the globe contributed pearls of wisdom on how to go about tackling inevitable turf battles from other specialties practicing...
Abbott’s Esprit BTK scaffold system given US FDA approval for CLTI...
Abbott has announced that the US Food and Drug Administration (FDA) has approved the Esprit BTK everolimus-eluting resorbable scaffold system (Esprit BTK system), a...
Endovascular showdown: CX 2024 sets the stage for BASIL-3 first-time data...
At the Charing Cross (CX) Symposium 2024 (23–25 April, London, UK), Andrew Bradbury (University of Birmingham, Birmingham, UK) and the BASIL-3 team of triallists...
FDA Breakthrough Device designation granted for DynamX BTK for use in...
Elixir Medical has announced Breakthrough Device designation by the Food and Drug Administration (FDA) for its novel DynamX BTK System, an implant for use...
US FDA Breakthrough Device designation granted for Biotronik’s Freesolve BTK resorbable...
Biotronik has been granted Breakthrough Device designation (BDD) from the US Food and Drug Administration (FDA) for the Freesolve below-the-knee (BTK) resorbable magnesium scaffold...
IVUS use in claudicants not associated with improved outcomes, claims data...
The use of intravascular ultrasound (IVUS) for the treatment of claudication doubled over a four-year period but there was “no clear relationship between IVUS...
Landmark BEST-CLI trial gains recognition as top cardiovascular advance in 2023
The American Heart Association (AHA) has named the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) trial one of...
Make a ‘PLAN’ for CLTI by tuning into new webinar
An upcoming webinar is set to provide insights for healthcare professionals aiming to enhance their expertise in treating patients with chronic limb-threatening ischemia (CLTI)....
Breakthrough Device designation granted for Efemoral scaffold system designed to treat...
Efemoral Medical has announced the granting of Food and Drug Administration (FDA) Breakthrough Device status for its novel Efemoral vascular scaffold system (EVSS) designed...
The top 10 most popular Vascular Specialist stories of January 2024
In January, the most read stories from Vascular Specialist include a U.S. Aortic Research Consortium analysis of F/BEVAR preoperative risk factors in AAAs/TAAAs; a...
UK MHRA update: Paclitaxel-coated device increased mortality risk is withdrawn for...
Following a review, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) has updated guidance on the use of paclitaxel-coated devices stating that such devices...
BEST-CLI: A year down the road
A dedicated session at the 2023 VEITHsymposium (Nov. 14–18) in New York City aimed to unpack the ways in which clinical practice and attitudes...
SVS receives CMSS grant to advance diagnostic excellence
The Society for Vascular Surgery (SVS) has received a $100,000 grant from the Council of Medical Specialty Societies (CMSS) to promote diagnostic excellence across...
Two-year SWING data ‘continue to show promise’ for sirolimus DCB in...
Two-year data from the SWING trial, a first-in-human study of the safety and performance of the Sundance sirolimus drug-coated balloon (DCB; Surmodics), have been...
PROMISE II 12-month data show durable outcomes with the LimFlow system...
One-year results from the PROMISE II US pivotal trial demonstrate the durability of outcomes of transcatheter arterialisation of the deep veins (TADV) using the...
The top 10 most popular Vascular Specialist stories of October 2023
Last month, the most popular stories from Vascular Specialist included The Centers for Medicare & Medicaid Services (CMS) confirmation of carotid artery stenting coverage expansion;...
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
A press release details that, under the terms...
CLTI: European cohort study provides ‘strong positive evidence’ for surgery over...
A recently published study has shown that lower limb bypass surgery offered a significantly higher probability of amputation-free survival and wound healing compared with...
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough...
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in...
MVSS 2023: Human Acellular Vessel proves ‘safe, effective bypass conduit’ in...
An investigator-sponsored clinical study conducted at the Mayo Clinic in Rochester, Minnesota, of the investigational Human Acellular Vessel (HAV) in patients with chronic limb-threatening...
The top 10 most popular Vascular Specialist stories of September 2023
Last month, the most read stories from Vascular Specialist included data releases from the recent Midwestern Vascular Surgical Society (MVSS) using direct revascularization of segmental...
When women are PIs: A story foretold on the vascular frontlines
“Multifactorial” issues persist in gender representation in vascular leadership and trial enrollment, leading women vascular surgeons tell Vascular Specialist.
"We would have fewer untoward side...
FDA approves LimFlow system for ‘no-option’ CLTI patients
The Food and Drug Administration (FDA) today announced approval of LimFlow therapy—a novel and minimally invasive procedure designed to bypass blockages in arteries of...
SVS responds to New York Times article on overuse of vascular...
In an official Society response, SVS President Joseph Mills, MD, tackles recent coverage in the mainstream media of inappropriateness in vascular care.
There have been...
Second edition of VSITE review text released
The second edition of a hit trainee-created textbook primarily aimed at those taking the Vascular Surgery In-Training Exam (VSITE) has hit the shelves.
The Vascular...
VAM 2023 attendees have their say on the impact of BEST-CLI...
As the vascular community continues to unpack the key learnings from two of the biggest trials to date in chronic limb threatening ischemia—BEST-CLI and...
New analysis probes BEST-CLI trial against real-world setting data
A new analysis of chronic limb-threatening ischemia (CLTI) treatment outcomes was presented at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions...
The Big Interview: Pioneering surgeon recounts career as new VAM lectureship...
Vascular Specialist medical editor Malachi Sheahan III, MD, sits down with Frank J. Veith, MD, to discuss his new book, The Medical Jungle, ahead of the...
Frailty status beats WIfI score as mortality predictor in all-comer CLTI...
A study presented during Plenary Session 3 at last week’s Vascular Annual Meeting (VAM), concluded that the Wound, Ischemia, and Foot Infection (WIfI) stage...
BEST-CLI investigators implore a move beyond endo vs. open ‘battle’ in...
The principal investigators behind the BEST-CLI trial struck a conciliatory tone during the inaugural Frank J. Veith Distinguished Lecture yesterday morning in which they...
Special VAM session underscores ‘complementary’ nature of open and endovascular strategies...
A dedicated session at VAM 2023 saw speakers and delegates gather to debate, analyse and consider the implementation of the BEST-CLI and BASIL-2 randomized-controlled...
The global burden of CLTI: ESVS President points toward need for...
Early-bird VAM 2023 attendees yesterday gained broad insight into the issues facing vascular surgeons around the world, with the tone set from the opening...
BEST-CLI vs. BASIL-2: Different questions yield different answers
Medical editor Malachi Sheahan III, MD, takes a look at seemingly conflicting results from the landmark BEST-CLI and BASIL-2 trials, and asks what they...
BASIL-2 and BEST-CLI: A tale of two limb trials
Optimal treatment of patients with chronic limb-threatening ischemia (CLTI) has been an ongoing debate within the vascular community, fueled by growing numbers of patients,...
Urban residents have smaller risk of mortality from chronic limb-threatening ischemia
A new study using data from millions of patients hospitalized across the U.S. has determined whether population density and associated urban versus suburban versus...
Insights from largest chronic limb-threatening ischaemia study to inform quality of...
Data from a cohort of one million patients with chronic limb-threatening ischaemia (CLTI) were recently presented as late-breaking clinical research at the Society for Cardiovascular...
New analysis of chronic limb-threatening ischaemia patients places BEST-CLI trial into...
A new analysis of chronic limb-threatening ischaemia (CLTI) treatment outcomes was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography &...
Vascular Specialist–May 2023
In this month's issue:
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients (p. 1 and 3)
A vascular mission: Defying assumptions in the...
Government Grand Rounds: Educating through advocacy
Since the initial launch of the Cancer Moonshot in 2016, the cancer community has made tangible progress towards ambitious goals, including accelerating scientific discovery...
BASIL-2 points towards endovascular-first revascularization strategy in CLTI patients
A question from Manj Gohel, MD, from Cambridge University Hospitals in Cambridge, England, on what the 2023 Charing Cross (CX) International Symposium audience should...
Results from PROMISE II pivotal trial published, reinforcing ‘ transformational value’...
Results from the PROMISE II pivotal trial investigating transcatheter arterialization of the deep veins using the LimFlow system in so-called no-option chronic limb-threatening ischemia...
SCVS 2023: Endovascular-first or -only approach to all CLTI patients ‘is...
Michael S. Conte, MD, one of the foremost experts in the field of peripheral arterial disease (PAD), took attendees of the 2023 annual meeting...
Florida hospital targets lingering disparities in limb salvage with region’s first...
This advertorial is sponsored by Tampa General Hospital.
Operating in Tampa, Florida, Charles J. Bailey, MD, and his partners in the Division of Vascular Surgery...
VESS 2023: pMAC score found to be ‘important predictor’ of CLTI...
Having observed a strong relationship between calcification and subsequent limb loss, a research team led by investigators from the University of California San Francisco...
BioGenCell begins recruitment for clinical trial of stem cell-based treatment for...
BioGenCell has announced that it is recruiting for an international clinical trial to assess the company's stem cell-based therapy for chronic limb-threatening ischemia patients...
Early data show ‘dramatic improvement’ in amputation-free survival after initiation of...
This advertorial is sponsored by Tampa General Hospital.
In cases of acute limb ischemia (ALI), time is of the essence, says Charles J. Bailey, MD—from...
BEST-CLI: Analysis finds correlation between WIfI stage four CLTI and reports...
The BEST-CLI dataset has revealed a correlation between wounds, ischemia and foot infection (WIfI) stage and poorer quality of life due to mental, rather...
SVS Foundation changes name of program aimed at providing care for...
The Society for Vascular Surgery (SVS) Foundation program formerly known as VISTA has a new name. VISTA—an acronym for Vascular Volunteers In Service To...
Vascular community starts process of wrestling with findings from BEST-CLI
One of the earliest multispecialty public gatherings of the vascular community following the release of the first results from the BEST-CLI randomized controlled...
The 10 most popular Vascular Specialist stories of November 2022
Among November's most read Vascular Specialist stories were updates from the BEST-CLI trial in the form of new data and funding; a guest...
Vascular Specialist–December 2022
In this issue:
Women in vascular: Annual summit dedicated to tackling key issues related to women’s vascular health and female workforce seeks to ‘enable...
BEST-CLI: Optimal medical therapy adherence ‘well below’ recommended level at baseline
A significant proportion of patients enrolled in the BEST-CLI trial did not meet optimal medical therapy (OMT) guideline-based recommendations at the time of their...
Miss the SVS webinars? Take advantage of the recordings
The Society for Vascular Surgery (SVS) hosts a number of Town Halls, roundtables and webinars for the benefit of its members.
In the past few...
SWING trial 12-month data: Novel sirolimus DCB shows ‘great promise’ in...
The Sundance (Surmodics) sirolimus drug-coated balloon (DCB) has an “excellent” safety profile in a “challenging, real-world, predominantly CLTI population,” and has a primary...
Vascular Specialist–November 2022
In this issue:
First data from BEST-CLI are revealed at the American Heart Association (AHA) Scientific Sessions (p. 1 and 12–13)
The Society...
First data from BEST-CLI bring surgical bypass into the forefront of...
The first results from the BEST-CLI randomized controlled trial (RCT) of 1,830 patients show that surgical bypass with adequate single-segment great saphenous vein (GSV)...
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66%...
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint...
BEST-CLI attracts $3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a $3.3 million contribution toward the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb...
Roundtable for treating CLTI: GLASS will make it clear
The final of three roundtables on treating Chronic Limb-threatening Ischemia (CLTI) will cover the Global Limb Anatomic Staging System—GLASS.
The virtual roundtable, on GLASS staging...
VEITHsymposium to include world federation session
The World Federation of Vascular Societies (WFVS) is set to hold a session in November during the VEITHsymposium in New York City. The 90-minute session...
CLTI: Translating guidelines into practice
Clinical practice guidelines (CPG) are integral to helping achieve optimal patient care. The Society for Vascular Surgery (SVS) clinical guidelines are evidence-based and the...
Digging deep into DOACs for PAD post-revascularization in fight to stave...
This advertorial is sponsored by ACHL.
“It’s really sad—but it’s true: In the PAD space, we’re really behind. We’re behind in our understanding of the...
SVS Vascular Health Step Challenge asks surgeons to walk the walk
Most American adults take an average of 5,000 steps per day. In fact, this simple act—getting out and moving—can be the key to prevention...
The top 10 most popular Vascular Specialist items of June 2022
June's top stories spanned a range of presentations from the 2022 Vascular Annual Meeting (VAM) in Boston (June 15–18), covering topics including burnout...
First results from BEST-CLI poised to reveal ‘very low’ quality of...
An analysis from the Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI) trial presented at the 2022 Vascular Annual...
Researchers report higher three-year amputation and reintervention rates in Black and...
In a study of over 7,000 chronic limb-threatening ischemia (CLTI) patients, researchers found that Black and Hispanic patients had higher three-year amputation and reintervention...
Open surgical bypass to distal targets at the ankle is ‘viable’...
The Vascular and Endovascular Surgical Society (VESS) Paper Session at the Vascular Annual Meeting (VAM) in Boston on Wednesday, June 15, will see Othman...
Revascularization strategy for BTK intervention should hinge on diagnostic modality, LINC...
New data provide “another argument” for the use of intravascular ultrasound (IVUS) in below-the-knee (BTK) interventions. This is according to Michael Lichtenberg, MD, from Arnsberg...
Register today for two SVS courses
Registration has opened—along with early-bird pricing—for two Society for Vascular Surgery (SVS) in-person courses in coding and reimbursement, and peripheral artery disease (PAD) skills....
Silent coronary ischemia: FFRCT reduces cardiac death, myocardial infarction in carotid...
Diagnosis of silent, or unsuspected, coronary ischemia in patients undergoing carotid endarterectomy (CEA) using fractional flow reserve-computed tomography (FFRCT), with selective postoperative coronary revascularization,...
FDA grants IDE approval for Selution SLR drug-eluting balloon
MedAlliance’s Selution SLR drug-eluting balloon (DEB) has received investigational device exemption (IDE) approval from the Food and Drug Administration, making it the first limus...
New long-term data of paclitaxel devices continue to show no increased...
New long-term data from the SAFE-PAD (Safety assessment of femoropopliteal endovascular treatment with paclitaxel-coated devices) study were presented today as late-breaking clinical research at...
Tissue samples show paclitaxel effect in minority of CLTI patients receiving...
Paclitaxel effect was witnessed in tissue specimens of a minority of chronic limb-threatening ischemia (CLTI) patients treated with drug-coated balloons (DCBs)—but was not dependent...
Non-optimal therapy for CLTI ‘more prominent in females’
A real-world claims data analysis of nearly 200,000 patients with chronic limb-threatening ischemia (CLTI) showed that female patients were older, underwent vascular procedures less often, and...
SCAI releases multi-society position statement focused on core competencies for endovascular...
The Society for Cardiovascular Angiography & Interventions (SCAI) has released a position statement outlining competencies for endovascular specialists who provide care for chronic limb-threatening...
CLTI, VTE and post-thrombotic syndrome: Leading experts discuss crucial decision-making in...
This advertorial is sponsored by ACHL.
For Anahita Dua, MBChB, the stark realities and complexities of peripheral arterial disease (PAD) patients undergoing endovascular treatment for...
SCVS 2022: WIfI score does not predict successful healing after transmetatarsal...
A higher initial Wound, ischemia, and foot infection (WIfI) classification score at initial presentation in chronic limb-threatening ischemia (CLTI) patients who underwent a transmetatarsal...
PROMISE II U.S. pivotal trial of device designed for ‘no-option’ CLTI...
Enrollment has been completed in the PROMISE II pivotal trial of the LimFlow deep vein arterialization system designed to prevent amputations in so-called "no-option"...
Cook Medical receives FDA breakthrough designation for new drug-eluting stent
Cook Medical has received Breakthrough Device designation from the Food and Drug Administration (FDA) on a new drug-eluting stent (DES) for below the knee...
ISET 2022 audience hears latest data on endovascular therapies
At this year’s International Symposium on Endovascular Therapy (ISET), being held Jan. 16–19 in Hollywood, Florida, experts presented an array of late-breaking trial results...
CLI at a crossroads: Which direction now?
Vascular surgery once again finds itself at a crossroads, Michael Belkin, MD, chief of the division of vascular and endovascular surgery at Brigham and...
First patient enrolled in Disrupt BTK II study for long, calcified,...
Shockwave Medical has announced the start of the Disrupt BTK II postmarket study to assess the safety, effectiveness and optimal clinical use of the Shockwave...
Philips announces large-scale study outcomes on use of IVUS in peripheral...
Royal Philips has announced the results of a new large-scale real-world analysis of Centers for Medicare & Medicaid Services (CMS) data on the health...
WIfI system helps predict revascularization benefit for diabetic patients with CLTI,...
A retrospective study supports the use of the Wound, ischemia, and foot infection (WIfI) classification system to predict the revascularization benefit for diabetic patients with chronic limb-threatening ischemia...
PROMISE I 24-month results ‘validate the benefits of the LimFlow system’
LimFlow has announced 24-month results from the PROMISE I study of the LimFlow percutaneous deep vein arterialization system, confirming “excellent and sustained outcomes” for...
VIVA 2021: IVL ‘consistently’ treats real-world calcium in multiple peripheral vessel...
An interim analysis from the DISRUPT PAD III observational study showed that intravascular lithotripsy (IVL) performs “consistently well” across challenging peripheral vessels, lesions and...
‘Proceed cautiously in use of DCBs in CLTI patients with advanced...
The last several years have seen ongoing controversy and debate about the risks and benefits of paclitaxel-coated devices (PCDs) for patients with peripheral arterial...
PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable...
Medical device developer R3 Vascular has reported the "successful initiation" of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude...
VAM discussion on latest paclitaxel meta-analysis yields mix of caution, skepticism
A Vascular Annual Meeting (VAM) sponsored session on paclitaxel safety drew a mix of skeptical and cautious responses to the latest meta-analysis from interventional...
Veterans with claudication who undergo revascularization ‘significantly more likely to have...
Patients within the Veterans Affairs Administration healthcare system who underwent an intervention for intermittent claudication (IC) were consistently at three-to-four times greater risk of...
PRISTINE registry with Selution SLR sirolimus drug-eluting balloon completes enrollment
MedAlliance has announced completion of patient enrollment in the PRISTINE clinical trial with the Selution SLR 018 drug-eluting balloon (DEB) for the treatment of patients with below-the-knee...
LimFlow system a ‘cost-effective and high-value alternative’ to traditional therapies
Percutaneous deep vein arterialization (pDVA) with the LimFlow system offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...
Latest meta-analysis on paclitaxel in peripheral arterial disease provokes mixed reception
“There appears to be heightened risk of major amputation after use of paclitaxel-coated balloons in the peripheral arteries,” findings from a systematic review...
Introducing patient-reported outcomes into the VQI
Vascular specialists have long recognized that there is more to the treatment of peripheral arterial disease (PAD) than the immediate procedural success and early...
Philips announces positive two-year data from TOBA II BTK clinical trial
Royal Philips recently announced positive two-year results from the TOBA (Tack optimized balloon angioplasty) II below-the-knee (BTK) clinical trial.
The data show the Philips Tack endovascular...
One-year results from PROMISE I study of LimFlow system in ‘no-option’...
Twelve-month data from the full patient cohort in the PROMISE I study of the LimFlow percutaneous deep vein arterialization (pDVA) system have been...
Intermittent claudication and exercise therapy: A poor SET-up
Many of you may have already heard about the controversial Comparative Billing Reports (CBRs) that have been received by some of our vascular surgery...
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery...
MicroStent to treat PAD below the knee receives FDA breakthrough device...
Micro Medical Solutions (MMS) recently revealed Food and Drug Administration (FDA) breakthrough device designation for its MicroStent vascular stent. This novel technology is designed...
Lessons in PAD care from VA vascular surgeons
The care of patients with peripheral arterial disease (PAD) is challenging and costly. Every practicing vascular surgeon knows that when patients present with ulcerations,...
‘A reliable tool’: Positive findings for 2D perfusion angiography in CLTI...
Researchers suggest that in patients with chronic limb-threatening ischemia (CLTI), two-dimensional (2D) perfusion angiography is a “reliable tool” when used according to standardized methods. Jetty...
Study identifies ‘critical need’ for guidelines on appropriate use of atherectomy
No data currently exist to support the use of atherectomy over other procedures for the treatment of peripheral arterial disease (PAD), and the healthcare...
Patients with depression ‘less likely’ to go home after CLTI revascularization
A recent analysis established an association between depression and non-home discharge after revascularization for chronic limb-threatening ischemia (CLTI)—providing further evidence, the authors say, that...
WIfI score found to be accurate across racial groups
The wound, ischemia and foot infection (WIfI) score is as accurate a predictor of risk for limb loss in Black people as it is...
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for...
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated (drug-coated balloons...
The benefits of an academic research career in the VA
Every year a number of graduating vascular trainees look for jobs in academic surgery to develop a career as a surgeon-scientist in basic, translational...
SVS pushes out trio of mobile apps to aid CLTI treatment
The Society for Vascular Surgery (SVS) has launched three new mobile apps to help guide surgeons in the treatment and management of chronic limb-threatening...
Foot vein arterialization study shows 77.8% limb salvage rate
Foot vein arterialization (FVA) is a safe procedure with good early graft patency and a limb salvage rate of 77.8%, Qi Yan, MD, and...
Diabetes Awareness Month: The utility of SVS branding fliers for diabetic...
November is Diabetes Awareness Month. The Branding Toolkit can help SVS members promote the valuable care they provide those with the disease.
One of...
Previously described patient-centered clinical success measure after revascularization for diabetic foot...
Patient-centered clinical success after lower-extremity revascularization for people with diabetic foot wounds was achieved among 63% of patients in a new analysis—but researchers suggest...
Utilize new SVS Branding Toolkit
The new SVS Branding Toolkit—a robust set of tools designed to help members communicate their roles in comprehensive vascular care—is now available exclusively and...
CDC codifies CLI, CLTI in ICD-10-CM
The Centers for Disease Control and Prevention (CDC) has approved a proposal to distinctly recognize critical limb ischemia (CLI) and critical limb-threatening ischemia (CLTI)...
VA system delivers high quality services for veterans
Vascular surgery in the Veterans Health Administration has always been a robust service, developing into a mature specialty around the time of the Vietnam...
Medicare reimbursement fails to adequately cover cost of care after open...
For most patients with chronic limb-threatening ischemia (CLTI), Medicare reimbursement for lower extremity bypass surgery does not adequately account for case complexity in the...
‘Rapid reduction’ in amputations follows opening of multidisciplinary limb preservation service
A multidisciplinary limb preservation service under the leadership of vascular surgery in a level one trauma center was associated with an immediate and rapid...
Three weeks remain of VQI virtual sessions
SVS ONLINE—the virtual meeting staged by the Society for Vascular Surgery (SVS)—may be completed, but the Vascular Quality Initiative (VQI) virtual sessions have three...
Positive two-year data from ALPS registry of LimFlow system published
LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialization (pDVA) system. Results were published...
Quality: Global Vascular Guidelines pocket guide coming soon
The Global Vascular Guidelines (GVG), extensively researched and written by an international committee of leading vascular experts, will soon be available as a pocket...
Study: Link between IC revascularization and progression to CLTI established alongside...
PALM BEACH, Fla.—Revascularization of intermittent claudication (IC) patients is associated with an increased rate of progression to critical limb-threatening ischemia (CLTI)—as well as an...
New meta-analysis finds ‘no observed difference’ in mortality between paclitaxel and...
February 2020 brings another paclitaxel device meta-analysis of randomized controlled trials in chronic limb-threatening ischemia (CLTI) patients. Krystal Dinh, BMed, of Westmead Hospital, Sydney,...
Global vascular guidelines for CLTI are gaining traction but work remains...
The application of new global vascular guidelines for chronic limb-threatening ischemia (CLTI) provides an opportune and worthwhile window to revisit the concept of critical...